HC refuses to quash govt order for procuring coronary stents

Image
Press Trust of India Mumbai
Last Updated : Apr 22 2014 | 5:18 PM IST
Observing that the government can impose stringent technical requirements to provide best possible medical devices for the purpose of public health programmes, the Bombay High Court refused to quash and set aside bids issued by the state to procure coronary stents.
A city-based company Vascular Concepts Ltd, dealing in manufacture and import of medical devices, including coronary stents, which are used for relieving cardiac ailments, approached the High Court challenging the government's decision making it mandatory for the medical devices to be approved by not only the Drugs Controller General of India, but also by the US Food and Drug Administration.
The company sought quashing and setting aside of the government's order allotting bid to US-based companies - India Medtronics Ltd and Abbot Healthcare. According to the company, approval from the DCGI was sufficient.
The government, however, claimed that approval from both DCGI and USFDA was insisted upon in larger public interest and that it does not wish to take any chance in the matter of health of the patients who were likely to receive the stents.
A division bench of Justices V M Kanade and A K Menon accepted this contention and said the petitioner company has failed to establish that the government has acted in an arbitrary or malafide or in a manner that can be said to be against public interest.
"To provide the best possible devices and equipment for the purpose of its public health programme, the state opted for stringent technical requirements. No fault can be found for imposing these specifications," the Court said.
The Court further held that the stents being imported pursuant to the tender issued are to be used in hospitals under the Rajiv Gandhi Arogya Yojana.
"The state government in its endeavour to ensure that best possible equipment is obtained for discharge of its social responsibility has, therefore, taken a decision in public interest," the bench said while dismissing the petition.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 22 2014 | 5:18 PM IST

Next Story